公开(公告)号：US20220402985A1

公开(公告)日：2022-12-22

申请号：US17836425

申请日：2022-06-09

Applicant: Amgen Inc.

Inventor： Darren L. BATES ,  Zhi LIU ,  TaeWeon LEE ,  Mark L. MICHAELS ,  Zhulun WANG

IPC: C07K14/485 ,  A61P9/10

Abstract: The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.

公开(公告)号：US20220089689A1

公开(公告)日：2022-03-24

申请号：US17491715

申请日：2021-10-01

Applicant: AMGEN INC.

Inventor： Jason C. O'NEILL ,  Randal R. KETCHEM ,  TaeWeon LEE ,  Vishnu CHINTALGATTU ,  Jennitte LeAnn STEVENS

IPC: C07K14/81

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.